Summit Therapeutics Inc.
Summit Therapeutics Inc. scores highest on Anchor (59) and lowest on Price (3). Its PosiPenta is 36.34 out of 100, weaker than most similar companies.
On the Penta Grid this week, Summit Therapeutics Inc. is Grid #639 of 837 in the Healthcare sector in United States, and Grid #3,193 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. | 36.34 | 3 | 34 | 45 | 40 | 59 |
| Encompass Health Corporation | 65.95 | 43 | 61 | 98 | 57 | 70 |
| BrightSpring Health Services, Inc. | 57.22 | 20 | 82 | 84 | 51 | 49 |
| Penumbra, Inc. | 60.59 | 15 | 74 | 87 | 66 | 62 |
| DaVita Inc. | 62.56 | 35 | 75 | 78 | 50 | 75 |
| The Cooper Companies, Inc. | 62.04 | 66 | 76 | 56 | 58 | 54 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -13.18 |
| P/B ratio | 18.53 |
EEarnings
| Trailing EPS | ₹-105.13 |
| Forward EPS | ₹-110.82 |
NNitro
| Price | 1385.68 |
| 52-week high | 2768.52 |
| 52-week low | 1143.21 |
| Fall from 52-week high | 49.9% |
TTorque
| Return on equity (ROE) | -192.50% |
| Debt-to-equity | 0.03 |
AAnchor
| Beta (price swings) | -1.52 |
| Market cap | ₹1,10,542 Cr |
| Insider holding | 80.87% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Summit Therapeutics Inc.'s PosiPenta score?
Summit Therapeutics Inc.'s PosiPenta is 36.34 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Summit Therapeutics Inc. stand on the Penta Grid?
On the Penta Grid this week, Summit Therapeutics Inc. is Grid #639 of 837 in the Healthcare sector in United States, and Grid #3,193 of 4,000 in United States.
Which PosiPenta pillar is strongest for Summit Therapeutics Inc.?
Anchor (stability and dividends), with a score of 59 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Summit Therapeutics Inc.?
Price (valuation), with a score of 3 out of 100: much weaker than most similar companies.
Has Summit Therapeutics Inc.'s PosiPenta changed since last week?
Yes, it rose 10.42 points, from 25.92 to 36.34.
PositoAI is for research and education only and is not investment advice.